

HISTIOCYTOSIS UK

England & Wales · Charity number 1158789

Details

Other names HISTIOUK

Status Registered

Legal form CIO

Registered 2014-10-06

Register [View on the Charity Commission register](#)

Contact

Address Histio UK
PO Box 159
Liskeard
PL14 9DQ

Phone 07850740241

Email histio@histiouk.org

Website www.histiouk.org

Activities

Objects: THE OBJECT OF THE CIO IS THE RELIEF OF SICKNESS AND PRESERVATION OF GOOD HEALTH AMONG PATIENTS AFFECTED BY HISTIOCYTIC DISEASES THEIR FAMILIES AND CARERS, IN PARTICULAR BUT NOT EXCLUSIVELY BY:(I) THE PROMOTION AND FURTHERANCE OF SCIENTIFIC RESEARCH INTO THE PHYSIOLOGY AND PATHOLOGY OF HISTIOCYTES AND THE AETIOLOGY OF HISTIOCYTIC DISEASES, THE USEFUL RESULTS OF WHICH WILL BE DISSEMINATED FOR THE PUBLIC BENEFIT;(II) THE DEVELOPMENT OF MORE ACCURATE MEANS OF DIAGNOSIS, IMPROVED PROTOCOLS FOR MANAGEMENT OF PATIENTS AND ULTIMATELY MEASURES FOR PREVENTION OF HISTIOCYTIC DISEASES;(III) THE PROVISION AND DISSEMINATION OF INFORMATION, EDUCATION AND KNOWLEDGE IN SUPPORT OF PATIENTS AND FAMILIES AFFECTED BY THE DISEASE TO INCLUDE THE MEDICAL PROFESSIONS AND GENERAL PUBLIC;(IV) COLLABORATION WITH INTERESTED INDIVIDUALS AND ORGANISATIONS.

Activities: (i) the promotion and furtherance of scientific research. (ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases; (iii) the provision and dissemination of information, (iv) collaboration with interested individuals and organisations.

Classification

- **How:** Makes Grants To Organisations, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- Ireland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£128,548	£133,154	-	-
2024-03-31	£126,827	£139,292	-	-
2023-03-31	£153,130	£164,756	-	-
2022-03-31	£166,821	£97,393	-	-
2021-03-31	£121,621	£167,290	-	-

Trustees

Name	Role	Appointed
Mr A Kontoyannis	Chair	2014-08-01
Dr Rachel Tattersall		2021-11-18
Dr V Nanduri		2014-08-01
PETER BIENENSTOCK		2014-09-26
PROFESSOR PETER CHARLES LEONARD BEVERLEY		2014-08-01

HISTIOCYTOSIS UK

England & Wales - Charity number 1158789

Accounts

Charity Registration No. 1158789

HISTIOCYTOSIS UK

KNOWN AS

HISTIO UK

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

**HISTIOCYTOSIS UK
HISTIO UK
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	Mr A Kontoyannis, Chair Prof. P Beverley Dr V Nanduri Mr P Bienenstock Prof. M Collin Dr R Tattersall
Other officers	Lynn Jackson, Executive Director
Charity number	1158789
Principal address	PO Box 159 Liskeard Cornwall PL14 9DQ
Independent examiner	TC Group 33 Boston Road South Holbeach Spalding Lincolnshire PE12 7LR
Bankers	CAF Bank Limited 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ

**HISTIOCYTOSIS UK
HISTIO UK
CONTENTS**

	Page
Trustees' report	1 - 5
Statement of trustees' responsibilities	6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the financial statements	10 - 17

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT**

FOR THE YEAR ENDED 31 MARCH 2025

The trustees present their annual report and financial statements for the year ended 31 March 2025.

Resignations

Prof. C Booth on 31st August 2024

Objectives and activities

Public benefit

- The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:
- (i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytotic diseases, the useful results of which will be disseminated for the public benefit;
- (ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;
- (iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;
- (iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research. The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial Report

Investment policy and objectives

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

Financial review

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

Income & Expenditure Summary

The 2024-2025 income remained steady against the previous financial year. Charities are in general suffering from the continued downturn in the cost of living, raising ongoing concerns about the "cost of giving" in this economic climate.

We thank all of our generous donors, the individuals, community groups, schools, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

Grant Awards

Histio UK placed a call for Research Papers, after substantial review by the Scientific Review Board and confirmation of the Board of Trustees an award offer was made to: Dr Claire Shannon-Lowe and her team for a project to Understand the role of Myeloid derived suppressor cells in the pathogenesis of Epstein Barr virus-associated HLH.

Grants Received

Nil in the financial year

Chairperson's Statement

Financial

Reflecting on this past year of operation, we acknowledge the support received in terms of funds and the contributions of our volunteers and Histio Champions. We also recognise that the current economic climate affects not only us but also our Histio Community and others, making it a challenging period for everyone.

The Charity acknowledges the likelihood of reduced income for the future and continues to adjust practices and budgets accordingly.

We are very pleased to have continued and further developed our various Histiocytic information guides and social media platforms allowing us to engage further with our Patients, Parents and Supporters.

In collaboration with our partners, we will maintain our commitment to providing histiocytic professionals, patients, and families with the most current information regarding these serious and devastating disorders as it becomes available.

Thank you all.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

Partnerships

Hi-HASC- Haemophagocytic Lymphohistiocytosis (HLH) Across Speciality Collaboration
Histio UK provides website administrative support to this amazing group.

UK Histio Registry –

Histio UK provides website administration to this established registry program.

PPPIE Panel – Patient, Parent, Public Involvement & Engagement Panel

Histiocytosis UK is committed to meaningful patient and public involvement and public engagement for and on behalf of not only its own Grant Fund Awards but to appraise those of other Researchers and or Organisations in the field of research with priority to those of Histiocytic diseases.

Our vision with regards to patient, parent and public involvement and engagement is-

“to establish a culture within Histiocytosis UK where our community has the skills and resources to optimise and deliver patient and public involvement and engagement and it is integrated in to our ways of working and throughout the research we fund and appraise”

Histiocytosis UK has, in consultation with researchers, public contributors and involvement professionals, identified 6 aims that will guide Histiocytosis UK and its engagement programme to work towards it's vision that No one should die of Histiocytosis:

- Ensure our research community incorporates patient and public involvement and engagement throughout research.
- Incorporate relevant involvement throughout our funding processes.
- Lead by example in our involvement and engagement practice.
- Strengthen involvement and engagement practice of Histio UK's Patient, Parent & Public Involvement Engagement Panel.
- Inspire and encourage inclusive, innovative, diverse and creative patient, parent and public involvement and engagement.
- Improve the knowledge sharing of patient, parent and public involvement and engagement.

The Histiocyte Society

The HS is the organisation representing clinical and research professionals in the field of Histiocytic disorders.

The Nikolas Symposium on Histiocytosis

The Nikolas Symposium is the leading scientific think-tank focused on a group of rare diseases called Histiocytic disorders. This international research symposium is dedicated to fostering innovative research.

Awareness

Awareness

Histiocytosis UK 2024 /2025 – Bite Size-Lets Talk & Share your Voice

This year we expanded our Share your Voice program to include Bite-Size enabling Histio Professionals and Patients to share their experience and journeys.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)**

FOR THE YEAR ENDED 31 MARCH 2025

Plans for the future

Histio UK, remains at the forefront in challenging these devastating disorders, we will continue to build on the transfer of information and knowledge available nationally and internationally through our committee structure to parents, patients and medical professionals.

Structure, Governance and Management

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

**The Chair of the SRB for 2024-2025 - Professor Peter Beverley MBBS, DSc, FMedSci.
Vice-Chair - Professor Matthew Collin. BM, BCh, DPhil, MRCP, FRCPath.**

The Trustees regularly review the skills and composition of their body and conduct succession planning. They recruit new Trustees based on experience, empathy, and knowledge of the charity. This year, the Trustee Board introduced and collaborated with an elected Advisory Panel.

As we move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

Fundraising Regulation

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

Risk management

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.


HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

The trustees' report was approved by the Board of Trustees.



Mr A Kontoyannis, Chair
Trustee

Dated: 17-06-2025

HISTIOCYTOSIS UK
HISTIO UK
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 MARCH 2025

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**HISTIOCYTOSIS UK
HISTIO UK
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF HISTIOCYTOSIS UK**

I report to the trustees on my examination of the financial statements of Histiocytosis UK (the charity) for the year ended 31 March 2025.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Christopher McKenna ACA

TC Group
33 Boston Road South
Holbeach
Spalding
Lincolnshire
PE12 7LR

Dated: 23/7/25

**HISTIOCYTOSIS UK
HISTIO UK
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT**

FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Income from:			
Donations and legacies	3	123,185	121,963
Investments	4	5,363	4,864
Total income		<u>128,548</u>	<u>126,827</u>
Expenditure on:			
Raising funds	5	1,100	1,281
Charitable activities	6	131,783	138,011
Other expenditure	11	271	-
Total expenditure		<u>133,154</u>	<u>139,292</u>
Net expenditure and movement in funds		(4,606)	(12,465)
Reconciliation of funds:			
Fund balances at 1 April 2024		403,712	416,177
Fund balances at 31 March 2025		<u>399,106</u>	<u>403,712</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

HISTIOCYTOSIS UK
HISTIO UK
BALANCE SHEET
AS AT 31 MARCH 2025

	Notes	2025		2024	
		£	£	£	£
Fixed assets					
Tangible assets	13		387		850
Current assets					
Debtors	14	981		941	
Cash at bank and in hand		403,027		405,383	
		404,008		406,324	
Creditors: amounts falling due within one year	15	(5,289)		(3,462)	
Net current assets			398,719		402,862
Total assets less current liabilities			399,106		403,712
Net assets			399,106		403,712
The funds of the charity					
Unrestricted funds			399,106		403,712
			399,106		403,712

The financial statements were approved by the trustees on 17.06.2025


Mr A Kontoyannis, Chair
Trustee

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies (Continued)

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.5 Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Office equipment	33% reducing balance
------------------	----------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial Instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Donations and gifts	123,185	121,963
Donations and gifts		
Donations	122,926	120,569
Gift aid tax reclaimed	259	1,394
	<u>123,185</u>	<u>121,963</u>

4 Income from investments

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Interest receivable	5,363	4,864

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

5 Raising funds

	Unrestricted funds	Unrestricted funds
	2025	2024
	£	£
General fundraising and event expenses	1,100	1,281
	<u>1,100</u>	<u>1,281</u>

6 Charitable activities

	Charitable Expenditure	Charitable Expenditure
	2025	2024
	£	£
Staff costs	58,986	58,986
Depreciation	191	419
Outreach costs	8,878	11,937
Travelling	4,056	4,289
Insurance	1,268	1,170
Telephone	1,334	4,077
Computer expenses	871	2,218
Printing, postage, stationery and advertising	2,142	3,103
Accountancy, bookkeeping and payroll fees	4,116	1,584
Bank charges	60	60
Interest payable	-	143
	<u>81,902</u>	<u>87,986</u>
Grant funding of activities (see note 7)	49,881	50,025
	<u>131,783</u>	<u>138,011</u>

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

7 Grants payable

	Charitable Expenditure 2025 £	Charitable Expenditure 2024 £
Research costs	49,881	50,025
	<u>49,881</u>	<u>50,025</u>

8 Net movement in funds

	2025 £	2024 £
The net movement in funds is stated after charging/(crediting):		
Depreciation of owned tangible fixed assets	191	419
Loss on disposal of tangible fixed assets	271	-
	<u>462</u>	<u>419</u>

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

10 Employees

The average monthly number of employees during the year was:

	2025 Number	2024 Number
	<u>1</u>	<u>1</u>
Employment costs	2025 £	2024 £
Wages and salaries	58,986	58,986
	<u>58,986</u>	<u>58,986</u>

There were no employees whose annual remuneration was more than £60,000.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

11 Other expenditure

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Net loss on disposal of tangible fixed assets	271	-

12 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

13 Tangible fixed assets

	Office equipment £
Cost	
At 1 April 2024	
Disposals	5,490 (3,568)
At 31 March 2025	1,922
Depreciation and impairment	
At 1 April 2024	
Depreciation charged in the year	4,640
Eliminated in respect of disposals	191 (3,296)
At 31 March 2025	1,535
Carrying amount	
At 31 March 2025	387
At 31 March 2024	850

14 Debtors

	2025 £	2024 £
Amounts falling due within one year:		
Prepayments and accrued income	981	941

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

15 Creditors: amounts falling due within one year	2025	2024
	£	£
Other taxation and social security	2,655	1,950
Accruals and deferred income	2,634	1,512
	<u>5,289</u>	<u>3,462</u>

16 Analysis of net assets between funds

	Unrestricted funds
	2025
	£
At 31 March 2025:	
Tangible assets	387
Current assets/(liabilities)	398,719
	<u>399,106</u>
	Unrestricted funds
	2024
	£
At 31 March 2024:	
Tangible assets	850
Current assets/(liabilities)	402,862
	<u>403,712</u>

17 Related party transactions

There were no disclosable related party transactions during the year (2024 - none).

Document Activity Report

Document Sent

Wed, 23 Jul 2025 15:25:48 GMT

Document Activity History

Document history shows most recent activity first

Date

Activity

You can verify that this is a genuine Portal document by uploading it to the following secure web page:

<http://tcgroup2.accountantspace.co.uk/messages/VerifyDocument>

HISTIOCYTOSIS UK

England & Wales - Charity number 1158789

Accounts

Charity Registration No. 1158789

HISTIOCYTOSIS UK

KNOWN AS

HISTIO UK

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

**HISTIOCYTOSIS UK
HISTIO UK
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	Mr A Kontoyannis, Chair Prof. P Beverley Dr V Nanduri Mr P Bienenstock Prof. M Collin Prof. C Booth Dr R Tattersall
Other officers	Lynn Jackson, Executive Director
Charity number	1158789
Principal address	PO Box 159 Liskeard Cornwall PL14 9DQ
Independent examiner	TC Group 33 Boston Road Holbeach Spalding Lincolnshire PE12 7LR
Bankers	CAF Bank Limited 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ

**HISTIOCYTOSIS UK
HISTIO UK
CONTENTS**

	Page
Trustees' report	1 - 6
Statement of trustees' responsibilities	7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 - 18

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT**

FOR THE YEAR ENDED 31 MARCH 2024

The trustees present their report and financial statements for the year ended 31 March 2024.

Objectives and activities

Public benefit

- The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:
 - (i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytocytic diseases, the useful results of which will be disseminated for the public benefit;
 - (ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;
 - (iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;
 - (iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research. The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial Report

Investment policy and objectives

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024**

Financial review

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

Income & Expenditure Summary

The 2023-2024 income was steady against the previous financial year. Charities in general suffering from the continued downturn in the cost of living raising concerns in the "cost of giving" in this economic climate.

We thank all of our generous donors, the individuals, community groups, schools, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

Grant Awards

In 2023 Histo UK placed a call for Research Papers, eleven applications were received. After substantial review by the Scientific Review Board and confirmation of the Board of Trustees in February 2024 an award offer was made to: Tatiana von Bahr Greenwood; MD, PhD and her team for a project to Establish a European CNS-LCH Registry in the sum of £50,000 made in February 2024.

Grants Received

Nil in the financial year

Chairman's Statement

Financial

This year continues to place a strain on our Charity income, in light of this we have adjusted our practices and budgets.

Reflecting on this past year of operation we are grateful for the amazing support that we have received, both in funds and the time and energy of our amazing volunteers and Histo Champions. We continue to recognise that the current economic climate affects not only us, but all of our Histo Community and beyond remaining a very difficult period for all.

Despite reduced income we have been able to continue our Information Support services and Partnership Projects.

We are very pleased to have continued and further developed our various Histiocytic information guides and social media platforms allowing us to engage further with our Patients, Parents and Supporters.

In association with our partners, we will continue to support histiocytic professionals, patients and families with up-to-date information on these devastating disorders as it becomes available.

Thank you all.

Partnerships

HI-HASC- Haemophagocytic Lymphohistiocytosis (HLH) Across Speciality Collaboration
Histio UK provides website administrative support to this amazing group.

UK Histio Registry –

Histio UK provides website administration to this established registry program.

PPPIE Panel – Patient, Parent, Public Involvement & Engagement Panel

Histiocytosis UK is committed to meaningful patient and public involvement and public engagement for and on behalf of not only its own Grant Fund Awards but to appraise those of other Researchers and or Organisations in the field of research with priority to those of Histiocytic diseases.

Our vision with regards to patient, parent and public involvement and engagement is-

“to establish a culture within Histiocytosis UK where our community has the skills and resources to optimise and deliver patient and public involvement and engagement and it is integrated in to our ways of working and throughout the research we fund and appraise”

Histiocytosis UK has, in consultation with researchers, public contributors and involvement professionals, identified 6 aims that will guide Histiocytosis UK and its engagement programme to work towards it's vision that No one should die of Histiocytosis:

- Ensure our research community incorporates patient and public involvement and engagement throughout research.
- Incorporate relevant involvement throughout our funding processes.
- Lead by example in our involvement and engagement practice.
- Strengthen involvement and engagement practice of Histio UK's Patient, Parent & Public Involvement Engagement Panel.
- Inspire and encourage inclusive, innovative, diverse and creative patient, parent and public involvement and engagement.
- Improve the knowledge sharing of patient, parent and public involvement and engagement.

The Histiocyte Society

The HS is the organisation representing clinical and research professionals in the field of Histiocytic disorders. They have agreed to share their virtual educational programme with us during the 2023-2024 period.

The Nikolas Symposium

Offering the opportunity to showcase new ideas, facilitate aspirational thinking, and develop innovative research.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)**

FOR THE YEAR ENDED 31 MARCH 2024

Awareness

Histiocytosis UK 2024 – Virtual Forum on 18th January

Building on previous years, the format of the 2024 programme for the Virtual Forum included the delivery of Abstracts, enabling a platform for not only established specialists but introduced emerging new talent in the field of Histiocytic disorders to a specialists audience from the UK and around the world.

HLH & Hyperinflammatory syndrome - Host: Dr Rachel Tattersall

Abstract Presenters

- A B Verbeek
- Elena Sienei
- Daniel Gtro

Speakers

Dr. Bitu Shakoory - Translational Autoinflammatory Diseases Section, National Institutes of Health Bethesda, Maryland, USA.

A Multi-Disciplinary Approach to [Diagnosis and Management] of Early/Suspected Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

Dr. Jessica Manson - Consultant Rheumatologist at UCLH, and Associate Honorary Professor at UCL.

A practical approach to the management of patients with HLH in the UK

Langerhans Cell Histiocytosis & other rarer disorders - Host Prof. Matthew Collin

Dr. Carl Allen - Milton and Allene Nirken Chair In Paediatric Oncology, Texas Children's Hospital Co-Director, Histiocytosis Program Co-Director, Lymphoma Program
Director of Research, Global Haematology-Oncology Paediatric Excellence (HOPE)
Professor, Department of Paediatrics, Section of Haematology-Oncology, Baylor College of Medicine.

LCH2024: Progress, Chaos and Opportunities?

Plans for the future

Histio UK, remains at the forefront in challenging these devastating disorders, we will continue to build on the transfer of information and knowledge available nationally and international through our committee structure to parents, patients and medical professionals.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)**

FOR THE YEAR ENDED 31 MARCH 2024

Structure, governance and management

Organisational structure

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

The Chair of the SRB for 2023-2024

Professor Peter Beverley MBBS, DSc, FMedSci

Vice-Chair

Professor Matthew Collin. BM, BCh, DPhil, MRCP, FRCPath

The Trustees review on a regular basis both to recruit new Trustee(s) for their experience, empathy and knowledge of the charity and to keep the skills and composition of the Trustee body and succession planning under review.

Move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

Fundraising Regulation

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

Risk management

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.


**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024**

Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

The trustees' report was approved by the Board of Trustees.



.....
**Mr A Kontoyannis, Chair
Trustee**

Dated: 06/06/2024

**HISTIOCYTOSIS UK
HISTIO UK
STATEMENT OF TRUSTEES' RESPONSIBILITIES**

FOR THE YEAR ENDED 31 MARCH 2024

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**HISTIOCYTOSIS UK
HISTIO UK
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF HISTIOCYTOSIS UK**

I report to the trustees on my examination of the financial statements of Histiocytosis UK (the charity) for the year ended 31 March 2024.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Christopher McKenna ACA

TC Group
33 Boston Road
Holbeach
Spalding
Lincolnshire
PE12 7LR

Dated: 11/01/24.....

HISTIOCYTOSIS UK
HISTIO UK
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2024

	Notes	Unrestricted funds 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Income from:					
Donations and legacies	3	121,963	141,526	9,900	151,426
Investments	4	4,864	1,704	-	1,704
Total income		126,827	143,230	9,900	153,130
Expenditure on:					
Raising funds	5	1,281	1,073	-	1,073
Charitable activities	6	138,011	153,783	9,900	163,683
Total resources expended		139,292	154,856	9,900	164,756
Net expenditure for the year/ Net movement in funds		(12,465)	(11,626)	-	(11,626)
Fund balances at 1 April 2023		416,177	427,803	-	427,803
Fund balances at 31 March 2024		403,712	416,177	-	416,177

The statement of financial activities includes all gains and losses recognised in the year.


All income and expenditure derive from continuing activities.

**HISTIOCYTOSIS UK
HISTIO UK
BALANCE SHEET**

AS AT 31 MARCH 2024

	Notes	2024		2023	
		£	£	£	£
Fixed assets					
Tangible assets	10		850		1,269
Current assets					
Debtors	11	941		855	
Cash at bank and in hand		405,383		417,306	
		<u>406,324</u>		<u>418,161</u>	
Creditors: amounts falling due within one year	12	<u>(3,462)</u>		<u>(3,253)</u>	
Net current assets			<u>402,862</u>		<u>414,908</u>
Total assets less current liabilities			<u>403,712</u>		<u>416,177</u>
Income funds					
Unrestricted funds			<u>403,712</u>		<u>416,177</u>
			<u>403,712</u>		<u>416,177</u>

The financial statements were approved by the Trustees on 06/06/2024


Mr A Kontoyannis, Chair
Trustee

**HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS**

FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies

(Continued)

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.5 Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Office equipment	33% reducing balance
------------------	----------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies

(Continued)

1.9 Financial Instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial Instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and legacies

	Unrestricted funds	Unrestricted funds	Restricted funds	Total
	2024	2023	2023	2023
	£	£	£	£
Donations and gifts	121,963	141,526	9,900	151,426
Donations and gifts				
Donations	120,569	141,401	9,900	151,301
Gift aid tax reclaimed	1,394	125	-	125
	121,963	141,526	9,900	151,426

4 Investments

	Unrestricted funds	Unrestricted funds
	2024	2023
	£	£
Interest receivable	4,864	1,704

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

5 Raising funds

	Unrestricted funds	Unrestricted funds
	2024	2023
	£	£
General fundraising and event expenses	1,281	1,073
	<u>1,281</u>	<u>1,073</u>
	<u><u>1,281</u></u>	<u><u>1,073</u></u>

6 Charitable activities

	Charitable Expenditure	Charitable Expenditure
	2024	2023
	£	£
Staff costs	58,986	57,246
Depreciation	419	624
Outreach costs	11,937	17,949
Travelling	4,289	5,114
Insurance	1,170	1,197
Telephone	4,077	2,131
Computer expenses	2,218	1,541
Printing, postage, stationery and advertising	3,103	3,960
Accountancy fees	1,584	1,476
Bank charges	60	72
Interest payable	143	-
	<u>87,986</u>	<u>91,310</u>
Grant funding of activities (see note 7)	50,025	72,373
	<u>138,011</u>	<u>163,683</u>
	<u><u>138,011</u></u>	<u><u>163,683</u></u>
Analysis by fund		
Unrestricted funds	138,011	153,783
Restricted funds	-	9,900
	<u><u>138,011</u></u>	<u><u>163,683</u></u>

**HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

FOR THE YEAR ENDED 31 MARCH 2024

7 Grants payable

	Charitable Expenditure 2024 £	Charitable Expenditure 2023 £
Research costs	50,025	72,373
	<u>50,025</u>	<u>72,373</u>
	<u><u>50,025</u></u>	<u><u>72,373</u></u>

8 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

9 Employees

The average monthly number of employees during the year was:

	2024 Number	2023 Number
	1	1
	<u>1</u>	<u>1</u>
Employment costs	2024 £	2023 £
Wages and salaries	58,986	57,246
	<u>58,986</u>	<u>57,246</u>
	<u><u>58,986</u></u>	<u><u>57,246</u></u>

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

10 Tangible fixed assets

	Office equipment
	£
Cost	
At 1 April 2023	5,490
	<u> </u>
At 31 March 2024	5,490
	<u> </u>
Depreciation and Impairment	
At 1 April 2023	4,221
Depreciation charged in the year	419
	<u> </u>
At 31 March 2024	4,640
	<u> </u>
Carrying amount	
At 31 March 2024	850
	<u> </u>
At 31 March 2023	1,269
	<u> </u>

11 Debtors

	2024	2023
	£	£
Amounts falling due within one year:		
Prepayments and accrued income	941	855
	<u> </u>	<u> </u>

12 Creditors: amounts falling due within one year

	2024	2023
	£	£
Other taxation and social security	1,950	1,813
Accruals and deferred income	1,512	1,440
	<u> </u>	<u> </u>
	3,462	3,253
	<u> </u>	<u> </u>

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

13 Analysis of net assets between funds

	Unrestricted funds 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fund balances at 31 March 2024 are represented by:				
Tangible assets	850	1,269	-	1,269
Current assets/(liabilities)	402,862	414,908	-	414,908
	<u>403,712</u>	<u>416,177</u>	<u>-</u>	<u>416,177</u>

14 Related party transactions

There were no disclosable related party transactions during the year (2023 - none).

Document Activity Report

Document Sent

Mon, 17 Jun 2024 08:25:00 GMT

Document Activity History

Document history shows most recent activity first

Date

Activity

You can verify that this is a genuine Portal document by uploading it to the following secure web page:

<http://tcgroup2.accountantspace.co.uk/messages/VerifyDocument>

HISTIOCYTOSIS UK

England & Wales - Charity number 1158789

Accounts

FOR THE YEAR ENDED 31 MARCH 2023

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

HISTIO UK

KNOWN AS

HISTIOCYTOSIS UK

Charity Registration No. 1158789

Trustees	Mr A Kontoyannis, Chair Prof. P Beverley Dr V Nanduri Mr P Bienenstock Prof. M Collin Prof. C Booth Dr R Tattersall
Other officers	Lynn Jackson, Executive Director 1158789
Charity number	
Principal address	PO Box 159 Liskeard Cornwall PL14 9DQ
Independent examiner	TC Group 33 Boston Road Holbeach Spalding Lincolnshire PE12 7LR
Bankers	CAF Bank Limited 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ

Page	
1 - 7	Trustees' report
8	Statement of trustees' responsibilities
9	Independent examiner's report
10	Statement of financial activities
11	Balance sheet
12 - 19	Notes to the financial statements

The trustees present their report and financial statements for the year ended 31 March 2023.

Objectives and activities

Public benefit

- The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:

- (i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytic diseases, the useful results of which will be disseminated for the public benefit;

- (ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;

- (iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;

- (iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research. The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial Report

Investment policy and objectives

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

Financial review

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

Income & Expenditure Summary

The 2022-2023 income was steady against the previous financial year. Charities in general suffering from the continued downturn in the cost of living raising concerns in the "cost of giving" in this economic climate.

We thank all of our generous donors, the individuals, community groups, schools, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

Grant Awards

Histio UK are very pleased to advise that two Research Grant Awards have been made during the period to value of £72,373. Dr Mark Bishton & his team for Liquid biopsy for the identification of malignancy associated haemophagocytic lymphohistiocytosis (HLH) and Dr E.P. Buddingh & her team for HLH Inflammatory Profile as a Predictor for stem cell transplant Outcome in children (HIPPO) study: cytokine dynamics to identify druggable targets and improve outcome.

Grants Received

We are incredibly pleased to announce that during 2022 Histio UK have been successful in our application to the National Lottery Community Fund.

The funders awarded Histio UK £9,900 for engagement of an Outreach Officer to help improve awareness and social media engagement.

Chairman's Statement

Financial

We recognise that this year our Charity income reflects the strain on all our accounts and personal budgets. The continuing generosity of our donors and supporters of time, energy and funds has enabled the Charity work to continue in these challenging times.

As we reflect on this past year of operation and the amazing support that we have received, the Charity recognises that the current economic climate effects not only us, but all of our Histo Community and beyond remaining a very difficult period for all.

Despite reduced income we have been able to continue our Information Support services and Partnership Projects.

We are very pleased to have continued and further developed our various Histoctic information guides and social media platforms allowing us to engage further with our Patients, Parents and Supporters.

In association with our partners, we will continue to support histiocytic professionals, patients and families with up-to-date information on these devastating disorders as it becomes available.

Thank you all.

Partnerships

HI-HASC - Haemophagocytic Lymphohistiocytosis (HLH) Across Specialty Collaboration
Histio UK provides website administrative support to this amazing group.

UK Histio Registry -

Histio UK provides website administration to this established registry program.

PPPPE Panel - Patient, Parent, Public Involvement & Engagement Panel

Histio UK is committed to meaningful patient and public involvement and engagement for and on behalf of not only its own Grant Fund Awards but to appraise those of other Researchers and or Organisations in the field of research with priority to those of Histio cytic diseases.

Our vision with regards to patient, parent and public involvement and engagement is-

“to establish a culture within Histio cytosis UK where our community has the skills and resources to optimise and deliver patient and public involvement and engagement and it is integrated in to our ways of working and throughout the research we fund and appraise”

Histio cytosis UK has, in consultation with researchers, public contributors and involvement professionals, identified 6 aims that will guide Histio cytosis UK and its engagement programme to work towards it's vision that No one should die of Histio cytosis:

- Ensure our research community incorporates patient and public involvement and engagement throughout research.
- Incorporate relevant involvement throughout our funding processes.
- Lead by example in our involvement and engagement practice.
- Strengthen involvement and engagement practice of Histio UK's Patient, Parent & Public Involvement Engagement Panel.
- Inspire and encourage inclusive, innovative, diverse and creative patient, parent and public involvement and engagement.
- Improve the knowledge sharing of patient, parent and public involvement and engagement.

Histio cytosis Hellas & The Nikolas Symposium

Histio UK continues to maintain a close working relationship with Histio cytosis Hellas (Artemis Association) and the scientific forum of the Nikolas Symposium.

The Histio cyte Society

The HS is the organisation representing clinical and research professionals in the field of Histio cytic disorders. They have agreed to share their virtual educational programme with us during the 2022-2023 period.

Awareness

Histiocytosis UK 2022 – Virtual Forum on 17th November 2022

Building on previous years, the format of the 2022 programme for the Virtual Forum included the delivery of Abstracts, enabling a platform for not only established specialists but introduced emerging new talent in the field of Histiocytic disorders to a specialists audience from the UK and around the world.

Haemophagocytic Lymphohistiocytosis (HLH) ADULT - Host: Prof. Claire Booth

Dr. Anupama Rao, Paediatric Haematology Consultant, GOSH & Dr. James Clark, Haematology Spr, GOSH
The National Paediatric HLH MDT – Audit.

Dr. Austen Worth, Paediatric Immunology at Great Ormond Street Hospital for Children and an associate professor in molecular immunology at UCL.
Novel therapies for HLH.

Prof. Claire Booth, Mahboubian Professor in Gene Therapy and Paediatric Immunology & Consultant in Paediatric Immunology, Great Ormond Street Hospital.
Small molecules to treat XLP and XIAP deficiency.

HLH & Hyperinflammatory syndrome – Hosts: Dr. Jessica Manson & Dr Rachel Tattersall

Abstracts presented by:

Dr. Betty Gratton - University College London Hospitals NHS Foundation Trust - Primary HLH in adults; genetic testing and use of Ruxolitinib.

Dr. Haris Khan - Frimley Health NHS Trust - When it's not just Typhoid fever

Dr. Thomas Nadin - Sheffield Teaching Hospitals NHS Foundation Trust - An evaluation of the causes and outcomes of haemophagocytic lymphohistiocytosis (HLH) in Sheffield Teaching Hospitals (2016 to 2021)

Speakers

Dr. Miriam Cox - Rheumatology Trainee, Sheffield -The HiHASC guideline for the investigation of HLH in adults.

Dr. Sam Clark - Consultant in ICU and anaesthetics, UCLH - The cardiac implications of HLH.

Dr. Grant Schliert - Paediatric Rheumatologist, Cincinnati Children's Hospital - HLH/MAS lessons learnt from rheumatological practice.

Plans for the future

Histo UK, will remain at the forefront in challenging these devastating disorders, we will continue to build on the transfer of information and knowledge available nationally and international through our committee structure to parents, patients and medical professionals.

Structure, governance and management

Organisational structure

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

The Chair of the SRB for 2022-2023

Professor Matthew Collin, BM, BCH, DPhil, MRCP, FRCPATH.

Vice-Chair

Professor Peter Beverley MBS, DSc, FMedSci.

The Trustees review on a regular basis both to recruit new Trustee(s) for their experience, empathy and knowledge of the charity and to keep the skills and composition of the Trustee body and succession planning under review.

As we move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

Fundraising Regulation

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

Risk management

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.

HISTIOCTOSIS UK
HISTIO UK

TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 31 MARCH 2023

Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

The Trustees' report was approved by the Board of Trustees.


.....
Mr A Kontoyannis, Chair

Trustee

Dated: 12/06/2023

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Dated: 27/01/23

TC Group
33 Boston Road
Holbeach
Spalding
Lincolnshire
PE12 7LR

Christopher McKenna ACA

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

Responsibilities and basis of report

I report to the trustees on my examination of the financial statements of Histocytosis UK (the charity) for the year ended 31 March 2023.

HISTOCYTOSIS UK
HISTIO UK
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF HISTOCYTOSIS UK

HISTIOCTOSIS UK
HISTIO UK
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2023

	Unrestricted funds 2023	Restricted funds 2023	Total Unrestricted funds 2023	Unrestricted funds 2022
Income from:				
Donations and legacies	141,526	9,900	151,426	166,787
Investments	1,704	-	1,704	34
Total income	143,230	9,900	153,130	166,821
Expenditure on:				
Raising funds	1,073	-	1,073	1,791
Charitable activities	153,783	9,900	163,683	95,603
Total resources expended	154,856	9,900	164,756	97,394
Net (expenditure)/income for the year/				
Net movement in funds	(11,626)	-	(11,626)	69,427
Fund balances at 1 April 2022	427,803	-	427,803	358,376
Fund balances at 31 March 2023	416,177	-	416,177	427,803


All income and expenditure derive from continuing activities.

The statement of financial activities includes all gains and losses recognised in the year.

HISTIOCTOSIS UK
HISTIO UK
BALANCE SHEET
AS AT 31 MARCH 2023

	Notes	2023	2022
		£	£
Fixed assets			
Tangible assets	10	1,269	1,893
Current assets			
Debtors	11	855	762
Cash at bank and in hand		417,306	428,187
Creditors: amounts falling due within one year	12	(3,253)	(3,039)
Net current assets		414,908	425,910
Total assets less current liabilities		416,177	427,803
Income funds			
Unrestricted funds		416,177	427,803

The financial statements were approved by the Trustees on 12/06/2023


Mr A Kontoyannis, Chair
Trustee

1 Accounting policies

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1 Accounting policies (Continued)

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.5 Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Office equipment

33% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1	Accounting policies
---	---------------------

1.9 Financial instruments
The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and legacies

	2023	2023	2022	2022
Unrestricted funds	Restricted funds	Total Unrestricted funds	Unrestricted funds	Restricted funds
Donations and gifts	141,526	9,900	151,426	166,787
Donations and gifts	141,401	9,900	151,301	166,412
Gift aid tax reclaimed	125	-	125	375
4 Investments	141,526	9,900	151,426	166,787
Interest receivable	1,704		1,704	34

5 Raising funds

Unrestricted funds	2023	2022
General fundraising and event expenses	1,073	1,791
	£	£
	1,073	1,791
	1,073	1,791

6 Charitable activities

Charitable Expenditure	2023	2022
Staff costs	57,246	56,914
Depreciation	624	933
Outreach costs	17,949	13,190
Traveling	5,114	1,957
Insurance	1,197	941
Telephone	2,131	1,666
Computer expenses	1,541	3,877
Printing, postage, stationery and advertising	3,960	3,531
Accountancy fees	1,476	1,404
Bank charges	72	106
Grant funding of activities (see note 7)	91,310	84,519
	72,373	11,084
	163,683	95,603
	163,683	95,603
Unrestricted funds	153,783	95,603
Restricted funds	9,900	-
	163,683	95,603

HISTIOCTOSIS UK
 HISTIO UK
 NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
 FOR THE YEAR ENDED 31 MARCH 2023

7	Grants payable					
		Charitable Expenditure	Charitable Expenditure			
		2023	2022			
		£	£			
	Research costs	<u>72,373</u>	<u>11,084</u>			
		72,373	11,084			
		<u>72,373</u>	<u>11,084</u>			
8	Trustees					
		None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.				
9	Employees					
		The average monthly number of employees during the year was:				
		2023	2022			
		Number	Number			
		<u>1</u>	<u>1</u>			
		1	1			
		<u>57,246</u>	<u>56,914</u>			
		£	£			
	Employment costs					
	Wages and salaries					

HISTIOCTOSIS UK
 HISTIO UK
 NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
 FOR THE YEAR ENDED 31 MARCH 2023

13 Analysis of net assets between funds

	Unrestricted funds 2023	Restricted funds 2023	Total Unrestricted funds 2023	Unrestricted funds 2022
Fund balances at 31 March 2023 are represented by:				
Tangible assets	1,269	-	1,269	1,893
Current assets/(liabilities)	414,908	-	414,908	425,910
	<u>416,177</u>	<u>-</u>	<u>416,177</u>	<u>427,803</u>

14 Related party transactions

There were no disclosable related party transactions during the year (2022 - none).

HISTIOCYTOSIS UK

England & Wales - Charity number 1158789

Accounts

Histiocytosis UK

known as

Histio UK

Annual Report and Financial Statements

for the Year Ended 31 March 2022

Histiocytosis UK

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 6
Statement of Trustees' Responsibilities	7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10
Notes to the Financial Statements	11 to 16

Histiocytosis UK

Reference and Administrative Details

Trustees

Mr A Kontoyannis, Chair
Prof. P Beverley
Dr V Nanduri
Mr P Bienenstock
Prof. M Collin
Dr C Booth
Dr R Tattersall (Appointed 18 November 2021)

Other Officers

Lynn Jackson, Executive Director

Principal Office

PO Box 159
Liskeard
Cornwall
PL14 9DQ

Charity Registration Number

1158789

Bankers

CAF Bank Limited
25 Kings Hill Avenue
Kings Hill West Malling
Kent
ME19 4JQ

Independent Examiner

TC Group
33 Boston Road
Holbeach
Spalding
Lincolnshire
PE12 7LR

Histiocytosis UK

Trustees' Report

The trustees present the annual report together with the financial statements of the charity for the year ended 31 March 2022.

Objectives and activities

Public benefit

The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:

(i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytotic diseases, the useful results of which will be disseminated for the public benefit;

(ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;

(iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;

(iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research.

The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial Report

Investment policy and objectives

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

Histiocytosis UK

Trustees' Report

Financial review

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

Income & Expenditure Summary

The 2021-2022 income improved slightly against the previous financial year.

We thank all of our generous donors, the individuals, community groups, schools, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

Grant Awards

In the light of the continued restrictions across not only the UK but around the world this year the Charity focused on the ongoing development of the UK Histiocytosis Registry project and awarded a further £11,084.

Grants Received

Nil

Chairman's Statement

Financial

Income this year has shown an improvement against 2020 enabling the Charity work to continue in these challenging times.

The Covid-19 pandemic continued to reduce the number of opportunities available to us all for fundraising, added to this our supporters faced the challenges of "lockdown" working and the rise in inflation rates. This contributed to reducing the pound in all of our pockets, as always, our supporters have risen to this challenge and enabled our continued work.

As we look back over this year's operation, we reflect on the amazing support that we have received during this second year of adversity, which remains a very difficult period for all.

Despite reduced income we have been able to continue our Information Support services and announce a Further Research award of £11,084 to the UK Histiocytosis Registry project - lead by Prof M. Collin.

In memory of our very good friend, colleague and Trustee we launched the Johannes Visser Invited Speaker Award for Clinicians and Researchers.

We are very pleased to have continued and further developed our various Histiocytic information guides and social media platforms allowing us to engage further with our Parents Patients and Supporters.

In association with our partners, we will continue to support histiocytic professionals, patients and families with up-to-date information on these devastating disorders as it becomes available.

Thank you all.

Partnerships

Hi-HASC- Haemophagocytic Lymphohistiocytosis (HLH) Across Speciality Collaboration
Histo UK continues to provide administrative support to this amazing group.

Awareness

Histiocytosis UK 2021 - Virtual Forum on 18th November 2021

Histiocytosis UK

Trustees' Report

The format of this years programme for the Virtual Forum changed to include the delivery of Abstracts, enabling a platform for not only established specialists but introduced emerging new talent in the field of Histiocytic disorders to a specialists audience from the UK and around the world.

Langerhans Cell Histiocytosis (LCH and Other Rarer) - Host Prof. Matthew Collin

Dr. Hanhua LIU - Presenting: Incidence & Survival of Langerhans Cell Histiocytosis: A National Registry Study in England 2013-2018

Abstracts

Dr. Vassilios Papadakis & Dr. Marina Servitzoglou - Greek Paediatric LCH National Registry Results over the last two decades.

Dr. Samir Patel - A Relapsing Disease Description RDD

Presentations

Dr. Eli Diamond

Member of the interdisciplinary team at Memorial Sloan Kettering treating and studying patients with histiocytic disorders such as Erdheim-Chester disease and Langerhans cell histiocytosis. Clinical Expertise - Neuro-Oncology; Adult Brain Tumours; Histiocytosis.

Presenting: Targeted treatment of histiocytosis in adults

Haemophagocytic lymphohistiocytosis (HLH) - Host: Dr Claire Booth

Dr Mark Bishton - Consultant Haematologist, Nottinghamshire University Hospitals Trust. **Dr. Hanhua Liu -** Senior Cancer Intelligence Analyst, Public Health England. **Peter Stilwell -** Senior Data Analyst, Public Health England.

Presenting: Histiocytic disease: NDRS approach to understanding rare disease and cancer at a population level

Abstracts

Andrew Duncombe - In A Single Large Centre Observational Cohort Study Of Hospitalised Covid-19 Patients, Secondary Hlh (Shlh) Was Rare But Hyperinflammation (Hi) Common And Hi Severity Predicted Response To Early Intervention With Dexamethasone Assessed By Day 28 Mortality.

Joseph Guppy - A Case Of Macrophage Activation Syndrome (Mas)/Haemophagocytic Lymphohistiocytosis (Hlh) Requiring Extra-Corporeal Membrane Oxygenation In A Patient With Severe Multisystem Lupus Erythematosus

Jeronimo Moreno-Cuesta - Hemophagocytes In Covid-19 Disease: A Novel Pilot Study Using Celsievstm Liquid Biopsy

HLH in Practice including HHASC representatives

Dr. Rob Sandler - Rheumatology Registrar, Sheffield Teaching Hospitals - Presenting: HLH after Bone Marrow Transplant

Dr Naina McCann - Infectious Diseases Registrar and Dr Pratyasha Saha Internal Medicine Speciality Trainee, University College London Hospital - Presenting: Complications and causes of death in HLH

Dr. Harry Wilson - Morkeh - Rheumatology Registrar, Hammersmith Hospital - Presenting: HLH in pregnancy

Presentations

Dr. Rebecca Marsh - Member of the paediatric haematologist-oncologist team affiliated with Cincinnati Children's Hospital Medical Center. - Presenting: Quercetin Suppresses XIAP Deficiency Associated Hyperinflammation

Plans for the future

Histio UK, will remain at the forefront in challenging these devastating disorders, we will continue to build on the transfer of information and knowledge available nationally and international through our committee structure to parents, patients and medical professionals.

Histiocytosis UK

Trustees' Report

Structure, governance and management

Organisational structure

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

The Chair of the SRB for 2021-2022

Professor Matthew Collin. BM, BCh, DPhil, MRCP, FRCPath.

Vice-Chair

Professor Peter Beverley MBBS, DSc, FMedSci.

The Trustees review on a regular basis both to recruit new Trustee(s) for their experience, empathy and knowledge of the charity and to keep the skills and composition of the Trustee body and succession planning under review.

As we move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

Fundraising Regulation

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

Risk management

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.

Histiocytosis UK

Trustees' Report

Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

The annual report was approved by the trustees of the charity on and signed on its behalf by:

Mr A Kontoyannis
Chair



Histiocytosis UK

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.


The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on and signed on its behalf by:

Mr A Komoyannis
Trustee



Histiocytosis UK

Independent Examiner's Report to the trustees of Histiocytosis UK

I report on the accounts of the charity for the year ended 31 March 2022 which are set out on pages 9 to 16.

Respective responsibilities of trustees and examiner

The trustees are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the next statement.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Christopher McKenna ACA

TC Group

Holbeach
Spalding
Lincolnshire
PE12 7LR

Date:.....

Histiocytosis UK

Statement of Financial Activities for the Year Ended 31 March 2022

	Note	Unrestricted £	Total 2022 £	Total 2021 £
Income and Endowments from:				
Charitable activities	2	166,787	166,787	121,530
Investment income	3	34	34	91
Total Income		<u>166,821</u>	<u>166,821</u>	<u>121,621</u>
Expenditure on:				
Raising funds	4	(1,791)	(1,791)	(1,173)
Research grants awarded	5	(11,084)	(11,084)	(82,562)
Charitable activities	6	(84,518)	(84,518)	(83,555)
Total Expenditure		<u>(97,393)</u>	<u>(97,393)</u>	<u>(167,290)</u>
Net movement in funds		69,428	69,428	(45,669)
Reconciliation of funds				
Total funds brought forward		<u>358,376</u>	<u>358,376</u>	<u>404,045</u>
Total funds carried forward	13	<u>427,804</u>	<u>427,804</u>	<u>358,376</u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2021 is shown in note 13.

Histiocytosis UK

(Registration number: 1158789)
Balance Sheet as at 31 March 2022

	Note	2022 £	2021 £
Fixed assets			
Tangible assets	10	1,893	904
Current assets			
Debtors	11	762	686
Cash at bank and in hand		<u>428,188</u>	<u>359,569</u>
		428,950	360,255
Creditors: Amounts falling due within one year	12	<u>(3,039)</u>	<u>(2,783)</u>
		425,911	357,472
Net current assets		<u>427,804</u>	<u>358,376</u>
Net assets		<u>427,804</u>	<u>358,376</u>
Funds of the charity:			
Unrestricted income funds			
Unrestricted		<u>427,804</u>	<u>358,376</u>
Total funds	13	<u>427,804</u>	<u>358,376</u>

The financial statements on pages 9 to 16 were approved by the trustees, and authorised for issue on and signed on their behalf by:

Mr A. Kontoyannis
Chair



Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2022

1 Accounting policies

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Histiocytosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the Charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Tangible fixed assets

Individual fixed assets costing £100.00 or more are initially recorded at cost.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2022

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Office equipment	33% reducing balance

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of is established when there is objective evidence that the will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2022

2 Income from charitable activities

	Unrestricted	Total	Total
	General	2022	2021
	£	£	£
Donations	166,412	166,412	84,970
Gift aid tax reclaimed	375	375	-
Lottery fund	-	-	36,560
	166,787	166,787	121,530

The total income from charitable activities for the year was £166,787 (2021 - £121,530) of which £166,787 (2021 - £84,970) was attributable to unrestricted funds and £Nil (2021 - £36,560) to restricted funds.

3 Investment income

	Unrestricted	Total	Total
	funds	2022	2021
	General	£	£
	£	£	£
Interest receivable and similar income;			
Interest receivable on bank deposits	34	34	91

The total investment income for the year was £34 (2021 - £91) of which £34 (2021 - £91) was attributable to unrestricted funds and £Nil (2021 - £Nil) to restricted funds.

4 Expenditure on raising funds

	Unrestricted	Total	Total
	funds	2022	2021
	General	£	£
	£	£	£
General fundraising and events expenses	1,791	1,791	1,173

The total expenditure on raising funds for the year was £1,791 (2021 - £1,173) of which £1,791 (2021 - £1,173) was attributable to unrestricted funds and £Nil (2021 - £Nil) to restricted funds.

5 Expenditure on research grants awarded

	Unrestricted	Total	Total
	funds	2022	2021
	General	£	£
	£	£	£
Research costs	11,084	11,084	82,562
	11,084	11,084	82,562

The total expenditure on research grants awarded for the year was £11,084 (2021 - £82,562) of which £11,084 (2021 - £82,562) was attributable to unrestricted funds and £Nil (2021 - £Nil) to restricted funds.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2022

6 Expenditure on charitable activities

		Unrestricted		
	Note	General £	Total 2022 £	Total 2021 £
Travelling		1,957	1,957	1,333
Insurance		940	940	901
Telephone		1,667	1,667	895
Computer expenses		3,877	3,877	1,716
Printing, postage, stationery and advertising		3,530	3,530	3,321
Accountancy fees		1,404	1,404	1,422
Bank charges		106	106	69
Depreciation		933	933	444
Staff costs	8	56,914	56,914	48,957
Outreach costs		13,190	13,190	24,497
		84,518	84,518	83,555

The total expenditure on charitable activities for the year was £84,518 (2021 - £83,555) of which £84,518 (2021 - £46,995) was attributable to unrestricted funds and £Nil (2021 - £36,560) to restricted funds.

7 Net incoming/outgoing resources

Net incoming/(outgoing) resources for the year include:

	2022 £	2021 £
Depreciation of fixed assets	933	444

8 Staff costs

The aggregate payroll costs were as follows:

	2022 £	2021 £
Staff costs during the year were:		
Wages and salaries	56,914	48,957

No employee received emoluments of more than £60,000 during the year.

9 Taxation

The charity is a registered charity and is therefore exempt from taxation.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2022

10 Tangible fixed assets

	Office equipment £	Total £
Cost		
At 1 April 2021	3,568	3,568
Additions	1,922	1,922
At 31 March 2022	5,490	5,490
Depreciation		
At 1 April 2021	2,664	2,664
Charge for the year	933	933
At 31 March 2022	3,597	3,597
Net book value		
At 31 March 2022	1,893	1,893
At 31 March 2021	904	904

11 Debtors

	2022 £	2021 £
Prepayments	762	686

12 Creditors: amounts falling due within one year

	2022 £	2021 £
Other taxation and social security	1,635	1,379
Accruals	1,404	1,404
	3,039	2,783

13 Funds

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
Unrestricted				
General	358,376	166,821	(97,393)	427,804

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2022

	Balance at 1 April 2020 £	Incoming resources £	Resources expended £	Balance at 31 March 2021 £
Unrestricted				
General	404,045	85,061	(130,730)	358,376
Restricted	-	36,560	(36,560)	-
Total funds	<u>404,045</u>	<u>121,621</u>	<u>(167,290)</u>	<u>358,376</u>

14 Analysis of net assets between funds

	Unrestricted funds General £	Total funds at 31 March 2022 £
Tangible fixed assets	1,893	1,893
Current assets	428,950	428,950
Current liabilities	(3,039)	(3,039)
Total net assets	<u>427,804</u>	<u>427,804</u>

Document Activity Report

Document Sent Fri, 29 Apr 2022 14:42:48 GMT

Document Approval Status Pending

Approval Activity Summary

Lynn Jackson Pending

Document Activity History

Document history shows most recent activity first

Date	Activity
------	----------

You can verify that this is a genuine Portal document by uploading it to the following secure web page:

<https://tcgroup2.accountantspace.co.uk/messages/VerifyDocument>

Document Activity Report

Document Sent

Tue, 14 Jun 2022 09:13:06 GMT

Document Activity History

Document history shows most recent activity first

Date

Activity

You can verify that this is a genuine Portal document by uploading it to the following secure web page:

<http://tcgroup2.accountantspace.co.uk/messages/VerifyDocument>

HISTIOCYTOSIS UK

England & Wales - Charity number 1158789

Accounts

Histiocytosis UK

known as

Histio UK

Annual Report and Financial Statements

for the Year Ended 31 March 2021

Histiocytosis UK

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 7
Statement of Trustees' Responsibilities	8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 to 17

Histiocytosis UK

Reference and Administrative Details

Trustees

Mr A Kontoyannis, Chair
Prof. P Beverley
Dr J Visser (Resigned on 07/11/2020)
Dr V Nanduri
Mr P Bienenstock
Prof. M Collin
Dr C Booth

Other Officers

Lynn Jackson, Executive Director

Principal Office

PO Box 159
Liskeard
Cornwall
PL14 9DQ

Charity Registration Number

1158789

Bankers

CAF Bank Limited
25 Kings Hill Avenue
Kings Hill West Malling
Kent
ME19 4JQ

Independent Examiner

Bulley Davey Limited
Chartered Certified Accountants
33 Boston Road
Holbeach
Spalding
Lincolnshire
PE12 7LR

Histiocytosis UK

Trustees' Report

The trustees present the annual report together with the financial statements of the charity for the year ended 31 March 2021.

Objectives and activities

Public benefit

The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:

(i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytotic diseases, the useful results of which will be disseminated for the public benefit;

(ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;

(iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;

(iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research.

The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial review

Investment policy and objectives

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

Histiocytosis UK

Trustees' Report

Financial review

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

Income & Expenditure Summary

The 2020–2021 income was greatly reduced this financial year due in the most part to the Covid 19 pandemic and public fundraising focused on the NHS Charities.

We thank our generous donors drawn from individuals, community groups, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

Grant Awards

Applications were invited for studies into the histiocytic disorder Paediatric Langerhans Cell Histiocytosis, for a maximum budget of £50,000 and duration of up to 24 months.

Histio UK considered scientific and clinical research on the epidemiology, pathogenesis, diagnosis, treatment and clinical care of patients with histiocytosis. Applicants were required to describe the likely impact of their research upon patients with histiocytosis and to outline a plan to attract further independent funding, using the award to drive forward new competitively funded research relevant to histiocytosis.

We are pleased to announce the following award was approved by the Trustees.

A UK & European multi centre project Lead By Dr Elena Sieni:-

MUTANT BRAF ALLELE BURDEN IN RELATION TO CLINICAL OUTCOME

Aim 1: bio banked and prospectively collected peripheral blood samples will be used to assess which of the two available assays (cell-free DNA isolated from plasma or DNA extracted from bulk blood cells) correctly reflects (changes in) disease burden. These results will lay the basis for a non-invasive monitoring protocol for improved clinical management of patients.
Aim 2: will analyse which type(s) of lineage cells in the blood actually express mutant BRAF alleles. This part of the project delivers data which help to further unravel the pathophysiology of LCH.

Grants Received

We are incredibly pleased to announce that during 2020 Histio UK have been successful in our application to the National Lottery Community Fund.

The funders awarded Histio UK £36,560 for our Histio Communities Project: Histio Connect - Let's Talk an inclusive on-line discussion platform for each of the different histiocytic disorders.

The platform will provide our Histio Champions the opportunity to chat, share their voices, their stories, achievements and memories enabling the opportunity to raise awareness, inspire others, learn more about other parents, patient, family's supporters and volunteers who shape this rare community.

Our Thanks to all our Histio community champions and HM Government for making this possible.

Histio UK Connect

We know that all Histio journeys come with unique challenges and we would like to hear about how we can best help you.

Can you help us try meet your needs with helpful information and programs through your histio journey?

However, you found us here at Histio UK whether you come to us newly diagnosed or have been with us for years, your input will guide us in providing the information you and many others may need in our Histio Community. Keep a look out in 2021 for our new Let's Talk & Connect Forum UK.

Histiocytosis UK

Trustees' Report

Chairman's Statement

Financial

This year has been a challenging time for the Charity and as we look back over this year's operation, we again reflect on the continued support that we have received during this unprecedented period for all. Despite reduced income we have been able to continue our Information Support services and announce a Research award of £50,000 to a UK & European multi centre project Lead By Dr Elena Sieni.

We are very pleased to have delivered various Histiocytic information guides and our outstanding community platform HistoUKConnect.org - Let's Talk programme.

In association with our partners, we will continue to support histiocytic professionals, patients and families with up-to-date information on these devastating disorders as it becomes available.

Thank you all.

Partnerships

Let's Talk-Histio UK Connect

Across Continents an Awareness Initiative for all Histiocytic disorders.

Let's Talk-Histio UK Connect - The Let's Talk Project has gathered together with Parent and Patient associations from across the continents via online discussion media.

In partnership with the USA, Canada, Greece, Italy, Spain, France, Argentina, and Brazil discussions will continue with a view to advance Patient and Parent support, information provision and knowledge sharing at local and international levels.

Hi-HASC- Haemophagocytic Lymphohistiocytosis (HLH) Across Speciality Collaboration
Histo UK continues to provide administrative support to this amazing group.

Awareness

November 2020 saw the 6th UK Histiocytosis Forum held virtually over two sessions including:

Haemophagocytic Lymphohistiocytosis

Hosted by Dr. Claire Booth

Dr Anupama Rao - Post HSCT outcomes in children with primary (genetic) HLH treated on Emapalumab.

Dr Alasdair Bamford - PIMS-TS/COVID related hyperinflammation in children.

Dr Jessica Manson - Covid 19 HLH and Hyperinflammation

Prof Joe West - Incident & Survival Population Cohort

Langerhans Cell Histiocytosis

Hosted by Prof Matthew Collin

Dr Milne - Advances in molecular diagnostics

Dr Donadieu - Targeted inhibitors

Plans for the future.

Histo UK, will remain at the forefront in challenging this devastating disease, we will continue to build on the transfer of information and knowledge available nationally and international through our committee structure to parents, patients and medical professionals.

Histiocytosis UK

Trustees' Report

Structure, governance and management

Organisational structure

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

The Chair of the SRB for 2020-2021

Professor Matthew Collin. BM, BCh, DPhil, MRCP, FRCPath.

Vice-Chair

Professor Peter Beverley MBBS, DSc, FMedSci.

The Trustees review on a regular basis both to recruit new Trustee(s) for their experience, empathy and knowledge of the charity and to keep the skills and composition of the Trustee body and succession planning under review.

As we move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

Sad News

Dr Johannes Visser retired from the Board of Trustees on 7th November 2020, and it is our sad duty to advise that Dr Johann Visser, died on the 20th December 2020, he was a consultant Paediatric Oncologist in Leicester and then Cambridge. Johann was a modest and gentle man and a dedicated and caring clinician, who made an enormous contribution to treatment of Langerhans Cell Histiocytosis (LCH) in the UK and world-wide.

He became a trustee of Histiocytosis UK in 2014 having previously served on the Board of Trustees at the Histiocytosis Research Trust. Johann contributed hugely to the Trust's activities with excellent, common-sense advice. He also played a major role in preparing the information booklet on Paediatric LCH that Histo UK distributes to doctors throughout the UK and in preparing material for the Histo UK website.

He worked tirelessly to improve the treatment of histiocytosis patients in the UK, setting up and running the national Histiocytosis Advisory Group. This is a computer-based forum for doctors treating histiocytosis patients. Any doctor needing advice can discuss a patient with doctors who are experts in histiocytosis, including of course Johann, at fortnightly "meetings". His clinical insight and advice will be desperately missed by everyone in the UK, who treats histiocytosis patients. Johann was also the lead investigator in the UK for the LCH IV international clinical trial. Because LCH is such a rare disease, such international trials are the only way in which new treatments can be properly assessed on enough patients to obtain reliable data. Running the trials is a laborious and time-consuming duty that Johann took on to the great benefit of all LCH patients. Recently kinase inhibitors, drugs such as Vemurafenib, that target the mutations in LCH have been developed and have raised the hope that they might revolutionise treatment of the disease. However, the introduction of any new therapy must be carefully assessed in clinical trials. Johann took part in the first international clinical trials of kinase inhibitor therapy in children, showing that these drugs may have a useful role in treatment of the disease and can be safely administered to children.

(Continued on Page 6)

Histiocytosis UK

Trustees' Report

Johann will be sorely missed by friends and colleagues throughout the UK and the international community of clinicians and scientists, who work on histiocytoses. It is a tragedy that such respected and influential figure has been taken from us at the early age of 52 years.

Fundraising Regulation

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

Risk management

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.

Histiocytosis UK

Trustees' Report

Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year, special thanks to all of those that make our Lets Talk - HistoUK Connect programme such a great success.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

Our thanks to our partner Charitable Trusts, Violets In Bloom and Giddo's Gift for their support in this difficult year.

The annual report was approved by the trustees of the charity on 04/06/21 and signed on its behalf by:



Mr A Kontoyannis
Chair

Histiocytosis UK

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on 04/06/21 and signed on its behalf by:


Mr A Kontoyannis
Trustee

Histiocytosis UK

Independent Examiner's Report to the trustees of Histiocytosis UK

I report on the accounts of the charity for the year ended 31 March 2021 which are set out on pages 10 to 17.

Respective responsibilities of trustees and examiner

The trustees are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the next statement.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Christopher McKenna ACA

Bulley Davey Limited
Chartered Certified Accountants
33 Boston Road
Holbeach
Spalding
Lincolnshire
PE12 7LR

Date:.....

Histiocytosis UK

Statement of Financial Activities for the Year Ended 31 March 2021

	Note	Unrestricted £	Restricted £	Total 2021 £	Total 2020 £
Income and Endowments from:					
Charitable activities	2	84,970	36,560	121,530	177,424
Investment income	3	91	-	91	302
Total Income		<u>85,061</u>	<u>36,560</u>	<u>121,621</u>	<u>177,726</u>
Expenditure on:					
Raising funds	4	(1,173)	-	(1,173)	(1,813)
Research grants awarded	5	(82,562)	-	(82,562)	(90,536)
Charitable activities	6	(46,995)	(36,560)	(83,555)	(74,474)
Total Expenditure		<u>(130,730)</u>	<u>(36,560)</u>	<u>(167,290)</u>	<u>(166,823)</u>
Net movement in funds		(45,669)	-	(45,669)	10,903
Reconciliation of funds					
Total funds brought forward		404,045	-	404,045	393,142
Total funds carried forward	13	<u>358,376</u>	<u>-</u>	<u>358,376</u>	<u>404,045</u>

All of the charity's activities derive from continuing operations during the above two periods.
The funds breakdown for 2020 is shown in note 13.

Histiocytosis UK

(Registration number: 1158789)
Balance Sheet as at 31 March 2021

	Note	2021 £	2020 £
Fixed assets			
Tangible assets	10	904	1,348
Current assets			
Debtors	11	686	671
Cash at bank and in hand		359,569	404,825
		360,255	405,496
Creditors: Amounts falling due within one year	12	(2,783)	(2,799)
Net current assets		357,472	402,697
Net assets		358,376	404,045
Funds of the charity:			
Unrestricted income funds			
Unrestricted		358,376	404,045
Total funds	13	358,376	404,045

The financial statements on pages 10 to 17 were approved by the trustees, and authorised for issue on 04/06/21 and signed on their behalf by:


Mr A. Kontoyannis
Chair

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

1 Accounting policies

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Histiocytosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the Charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Tangible fixed assets

Individual fixed assets costing £100.00 or more are initially recorded at cost.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Office equipment	33% reducing balance

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of is established when there is objective evidence that the will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

2 Income from charitable activities

	Unrestricted		Total 2021 £	Total 2020 £
	General £	Restricted £		
Donations	84,970	-	84,970	177,031
Gift aid tax reclaimed	-	-	-	393
Lottery fund	-	36,560	36,560	-
	84,970	36,560	121,530	177,424

The total income from charitable activities for the year was £121,530 (2020 - £177,424) of which £84,970 (2020 - £177,424) was attributable to unrestricted funds and £36,560 (2020 - £Nil) to restricted funds.

3 Investment income

	Unrestricted funds General £	Total 2021 £	Total 2020 £
	Interest receivable and similar income; Interest receivable on bank deposits	91	91

The total investment income for the year was £91 (2020 - £302) of which £91 (2020 - £302) was attributable to unrestricted funds and £Nil (2020 - £Nil) to restricted funds.

4 Expenditure on raising funds

	Unrestricted funds General £	Total 2021 £	Total 2020 £
	General fundraising and events expenses	1,173	1,173

The total expenditure on raising funds for the year was £1,173 (2020 - £1,813) of which £1,173 (2020 - £1,813) was attributable to unrestricted funds and £Nil (2020 - £Nil) to restricted funds.

5 Expenditure on research grants awarded

	Unrestricted funds General £	Total 2021 £	Total 2020 £
	Research costs	82,562	82,562
	82,562	82,562	90,536

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

The total expenditure on research grants awarded for the year was £82,562 (2020 - £90,536) of which £82,562 (2020 - £90,536) was attributable to unrestricted funds and £Nil (2020 - £Nil) to restricted funds.

6 Expenditure on charitable activities

	Note	Unrestricted General £	Restricted £	Total 2021 £	Total 2020 £
Trustees expenses		-	-	-	1,090
Travelling		1,333	-	1,333	8,649
Insurance		901	-	901	865
Telephone		895	-	895	1,023
Computer expenses		1,716	-	1,716	2,589
Printing, postage, stationery and advertising		3,321	-	3,321	3,298
Charitable donations		-	-	-	4,039
Accountancy fees		1,422	-	1,422	1,398
Bank charges		69	-	69	86
Depreciation		444	-	444	665
Staff costs	8	36,894	12,063	48,957	47,531
Outreach costs		-	24,497	24,497	3,241
		<u>46,995</u>	<u>36,560</u>	<u>83,555</u>	<u>74,474</u>

The total expenditure on charitable activities for the year was £83,555 (2020 - £74,474) of which £46,995 (2020 - £72,266) was attributable to unrestricted funds and £36,560 (2020 - £2,208) to restricted funds.

7 Net incoming/outgoing resources

Net (outgoing)/incoming resources for the year include:

	2021 £	2020 £
Depreciation of fixed assets	<u>444</u>	<u>665</u>

8 Staff costs

The aggregate payroll costs were as follows:

	2021 £	2020 £
Staff costs during the year were:		
Wages and salaries	<u>48,957</u>	<u>47,531</u>

No employee received emoluments of more than £60,000 during the year.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

9 Taxation

The charity is a registered charity and is therefore exempt from taxation.

10 Tangible fixed assets

	Office equipment £	Total £
Cost		
At 1 April 2020	<u>3,568</u>	<u>3,568</u>
At 31 March 2021	<u>3,568</u>	<u>3,568</u>
Depreciation		
At 1 April 2020	2,220	2,220
Charge for the year	<u>444</u>	<u>444</u>
At 31 March 2021	<u>2,664</u>	<u>2,664</u>
Net book value		
At 31 March 2021	<u>904</u>	<u>904</u>
At 31 March 2020	<u>1,348</u>	<u>1,348</u>

11 Debtors

	2021 £	2020 £
Prepayments	<u>686</u>	<u>671</u>

12 Creditors: amounts falling due within one year

	2021 £	2020 £
Other taxation and social security	1,379	1,413
Accruals	<u>1,404</u>	<u>1,386</u>
	<u>2,783</u>	<u>2,799</u>

13 Funds

	Balance at 1 April 2020 £	Incoming resources £	Resources expended £	Balance at 31 March 2021 £
Unrestricted				
General	404,045	85,061	(130,730)	358,376
Restricted	<u>-</u>	<u>36,560</u>	<u>(36,560)</u>	<u>-</u>
Total funds	<u>404,045</u>	<u>121,621</u>	<u>(167,290)</u>	<u>358,376</u>

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

	Balance at 1 April 2019 £	Incoming resources £	Resources expended £	Balance at 31 March 2020 £
Unrestricted				
General	390,934	177,726	(164,615)	404,045
Restricted	<u>2,208</u>	<u>-</u>	<u>(2,208)</u>	<u>-</u>
Total funds	<u>393,142</u>	<u>177,726</u>	<u>(166,823)</u>	<u>404,045</u>

14 Analysis of net assets between funds

	Unrestricted funds General £	Total funds at 31 March 2021 £
Tangible fixed assets	904	904
Current assets	360,255	360,255
Current liabilities	<u>(2,783)</u>	<u>(2,783)</u>
Total net assets	<u>358,376</u>	<u>358,376</u>